Literature DB >> 24297635

The influence of serum sodium concentration on prognosis in resected non-small cell lung cancer.

Naohiro Kobayashi1, Shingo Usui1, Masatoshi Yamaoka2, Hisashi Suzuki1, Shinji Kikuchi1, Yukinobu Goto1, Mitsuaki Sakai1, Yukio Sato1.   

Abstract

BACKGROUND: Hyponatremia is the most common electrolyte disorder and is a negative prognostic factor in several kinds of cancer. However, few reports have referred to hyponatremia in non-small cell lung cancer (NSCLC). In the present study, the authors examined the influence of preoperative serum sodium concentration on survival in completely resected NSCLC.
METHODS: A total of 386 completely resected NSCLC patients were retrospectively analyzed.
RESULTS: Kaplan-Meier survival curves showed that serum sodium concentration was a significant prognostic factor, and the log-rank statistical value was maximum (9.173, p = 0.002) when the cutoff value of serum sodium concentration was 139 mEq/L. The overall 5-year survival rate of the high-serum sodium concentration group (> 139 mEq/L) was 74.8% and that of the low-serum sodium concentration group (≤ 139 mEq/L) was 59.7%. Clinicopathological factors showed significant differences between the two groups for leukocyte count, neutrophil count, C-reactive protein, tumor size, and pleural invasion.
CONCLUSIONS: Low-serum sodium concentration, which was associated with tumor status and inflammation, had negative prognostic influence in completely resected NSCLC. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24297635     DOI: 10.1055/s-0033-1359713

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  10 in total

1.  The prognostic and predictive role of hyponatremia in patients with advanced non-small cell lung cancer (NSCLC) with bone metastases.

Authors:  S Rinaldi; M Santoni; G Leoni; I Fiordoliva; G Marcantognini; T Meletani; G Armento; D Santini; T Newsom-Davis; M Tiberi; F Morgese; M Torniai; M Bower; Rossana Berardi
Journal:  Support Care Cancer       Date:  2018-11-08       Impact factor: 3.603

2.  Prognostic value of preoperative hyponatremia and thrombocytosis in patients with epithelial ovarian cancer.

Authors:  Katrin Hefler-Frischmuth; Christoph Grimm; Lisa Gensthaler; Elisabeth Reiser; Richard Schwameis; Lukas A Hefler
Journal:  Wien Klin Wochenschr       Date:  2018-09-03       Impact factor: 1.704

3.  Efficacy of second-line treatment and importance of comorbidity scores and clinical parameters affecting prognosis in elderly patients with non-small cell lung cancer without epidermal growth factor receptor mutations.

Authors:  Sung Yong Lee; Eun Joo Kang; Suk Young Lee; Hong Jun Kim; Kyung Hoon Min; Gyu Young Hur; Jae Jeong Shim; Kyung Ho Kang; Sang Cheul Oh; Jae Hong Seo; Jun Suk Kim
Journal:  Oncol Lett       Date:  2017-11-03       Impact factor: 2.967

4.  Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy.

Authors:  Rossana Berardi; Matteo Santoni; Thomas Newsom-Davis; Miriam Caramanti; Silvia Rinaldi; Michela Tiberi; Francesca Morgese; Mariangela Torniai; Mirco Pistelli; Azzurra Onofri; Marc Bower; Stefano Cascinu
Journal:  Oncotarget       Date:  2017-04-04

5.  Impact of serum sodium concentration on survival outcomes in patients with invasive bladder cancer without metastasis treated by cystectomy.

Authors:  Wataru Nakata; Gaku Yamamichi; Go Tsujimura; Yuichi Tsujimoto; Mikio Nin; Masao Tsujihata
Journal:  Int J Urol       Date:  2018-12-02       Impact factor: 3.369

6.  Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study.

Authors:  Rossana Berardi; Candida Mastroianni; Giuseppe Lo Russo; Roberta Buosi; Daniele Santini; Agnese Montanino; Carlo Carnaghi; Marcello Tiseo; Rita Chiari; Andrea Camerini; Sandro Barni; Valeria De Marino; Daris Ferrari; Antonella Cristofano; Laura Doni; Federica Freddari; Daniele Fumagalli; Luigi Portalone; Roberta Sarmiento; Giovanni Schinzari; Francesca Sperandi; Marcello Tucci; Alessandro Inno; Libero Ciuffreda; Marita Mariotti; Cinzia Mariani; Miriam Caramanti; Mariangela Torniai; Rosaria Gallucci; Chiara Bennati; Paola Bordi; Lucio Buffoni; Achille Galeassi; Michele Ghidini; Emidio Grossi; Alessandro Morabito; Bruno Vincenzi; Emanuela Arvat
Journal:  Ther Adv Med Oncol       Date:  2019-09-27       Impact factor: 8.168

7.  Hyponatremia as a prognostic factor in non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Birgitte Sandfeld-Paulsen; Ninna Aggerholm-Pedersen; Anne Winther-Larsen
Journal:  Transl Lung Cancer Res       Date:  2021-02

8.  The V2 receptor antagonist tolvaptan counteracts proliferation and invasivity in human cancer cells.

Authors:  G Marroncini; C Anceschi; L Naldi; B Fibbi; F Baldanzi; M Maggi; A Peri
Journal:  J Endocrinol Invest       Date:  2022-05-23       Impact factor: 5.467

Review 9.  Managing hyponatremia in lung cancer: latest evidence and clinical implications.

Authors:  Ilaria Fiordoliva; Tania Meletani; Maria Giuditta Baleani; Silvia Rinaldi; Agnese Savini; Marzia Di Pietro Paolo; Rossana Berardi
Journal:  Ther Adv Med Oncol       Date:  2017-10-28       Impact factor: 8.168

10.  Prevalence and Prognostic Significance of Hyponatremia in Patients With Lung Cancer: Systematic Review and Meta-Analysis.

Authors:  Eszter Bartalis; Marin Gergics; Benedek Tinusz; Mária Földi; Szabolcs Kiss; Dávid Németh; Margit Solymár; Zsolt Szakács; Péter Hegyi; Emese Mezösi; László Bajnok
Journal:  Front Med (Lausanne)       Date:  2021-12-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.